Current clinical trials examine the effects of GDNF (and its relative Neurturin) delivery for PD, although with conflicting results, suggesting that improvements in both technology and biological understanding of GDNF action are required [7],[39]. This evidence concerns the gene GDNF and Parkinson disease.